AbbVie Declares $1.73 Quarterly Dividend, Reinforcing Long-Term Capital Allocation Strategy
- AbbVie declares a $1.73 quarterly dividend, payable May 15, 2026; record date April 15, 2026.
- AbbVie says dividends have risen over 330% since 2013 and it remains in the S&P Dividend Aristocrats.
- AbbVie frames the payout as supporting long-term growth, Allergan Aesthetics integration, immunology, neuroscience and oncology pipelines.
AbbVie declares quarterly payout as part of long-term capital plan
Dividend Policy Anchors Capital Allocation Strategy
AbbVie announces a quarterly cash dividend of $1.73 per share, payable May 15, 2026 to shareholders of record at the close of business on April 15, 2026. The company frames the declaration as part of its broader capital-allocation priorities and says the move complements disclosures tied to its full-year and fourth-quarter 2025 results.
The company says it has raised its dividend more than 330% since AbbVie’s 2013 inception and highlights membership in the S&P Dividend Aristocrats Index, which tracks firms that have increased payouts for at least 25 consecutive years. AbbVie presents the dividend decision as evidence of a sustained focus on returning cash to shareholders while maintaining investment in its business.
AbbVie positions the payout as aligned with its mission to fund long-term growth across key therapeutic areas. Executives emphasise that continuing dividend increases and other returns of capital sit alongside ongoing operational priorities, including integration of Allergan Aesthetics initiatives and the delivery of medicines in immunology, neuroscience and oncology.
Allergan Aesthetics and pipeline priorities
AbbVie reiterates its commitment to discovering and delivering innovative medicines and highlights product and services within the Allergan Aesthetics portfolio as part of its growth mix. The company stresses that aesthetic offerings, together with therapeutic pipelines in immunology, neuroscience and oncology, underpin its strategy to diversify revenue and support long-term shareholder returns.
Documentation and investor access
AbbVie points investors and the media to its website and PR Newswire for the full press release, detailed fourth-quarter and full-year 2025 financial results, regulatory filings and investor presentations. Media inquiries are directed to the company’s communications contact and investor queries to its investor relations team, with materials posted for confirmation and archival access.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…

